BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn® Trial at the 2024 Maxim Healthcare Virtual Summit
- NEW YORK , Oct. 7, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced its participation in the 2024 Maxim Healthcare Virtual Summit. Chaim Lebovits, President and CEO of BrainStorm, will join Jason McCarthy, Ph.D.
- 10/07/2024
|
BrainStorm Cell Therapeutics Announces Presentations on NurOwn® at 2024 Annual NEALS Meeting
- NEW YORK , Sept. 24, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the acceptance of two abstracts featuring NurOwn® (MSC-NTF or Debamestrocel) at the 2024 Annual Northeastern Amyotrophic Lateral Sclerosis Consortium (NEALS) Meeting, to take place October 21 - 24, in-person in Clearwater, Florida and virtually.
- 09/24/2024
|
BrainStorm Cell Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
- - Company reached alignment with the U.S. FDA on the Chemistry, Manufacturing, and Controls (CMC) aspects of its planned Phase 3b clinical trial for NurOwn® in ALS - SPA in place for Phase 3b NurOwn® trial in ALS - Enhanced leadership team with appointment of Hartoun Hartounian Ph.D. as EVP and Chief Operating Officer, and promotion of Dr. Bob Dagher to EVP and Chief Medical Officer - Conference call and webcast at 8.30am ET today NEW YORK , Aug. 14, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the Second Quarter ended June 30, 2023 and provided a corporate update.
- 08/14/2024
|
BrainStorm Cell Therapeutics to Announce Second Quarter Results and Provide a Corporate Update
- NEW YORK , Aug. 7, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will hold a conference call to update shareholders on financial results for the second quarter ended June 30, 2024, and provide a corporate update, at 8:30 a.m. Eastern Time on Wednesday, August 14, 2024.
- 08/07/2024
|
BCLI Update - Progress Supports Our 10x Plus Value Range Potential
- ACF Equity Research FROM ACF EQUITY RESEARCH HEALTHCARE TEAM LONDON , July 24, 2024 /PRNewswire/ -- NASDAQ: BCLI READ ACF EQUITY RESEARCH'S UPDATE NOTE HERE READ ACF EQUITY RESEARCH'S RELATED THEMATIC RESEARCH NOTE ON REGENERATIVE MEDICINE – NEURODEGENERATIVE DISEASE STEM CELLS & ALS/MND/LOU GEHRIG'S HERE UPDATE NOTE: BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI) develops NurOwn® stem cell therapy for Neurodegenerative diseases (NDDs) – BCLI's first target is ALS (MND/Lou Gehrig's). Since initiation – PIIIb rollout begins.
- 07/24/2024
|
Brainstorm Cell Therapeutics Inc. (BCLI) Corporate Mid-Year Update on NurOwn Program (Transcript)
- Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI ) Corporate Mid-Year Update on NurOwn Program July 8, 2024 8:00 AM ET Company Participants Joyce Lonergan - LifeSci Advisors Chaim Lebovits - President and Chief Executive Officer Haro Hartounian - Executive Vice President, Chief Operating Officer Bob Dagher - Executive Vice President, Chief Medical Officer Conference Call Participants Jason McCarthy - Maxim Group David Bautz - Zachs Small Cap Research Operator Greetings and welcome to the Brainstorm Cell Therapeutics Mid-Year 2024 Conference Call. At this time, all participants are in a listen-only mode.
- 07/08/2024
|
BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program
- A conference call and webcast will be held Monday, July 8, at 8:00 a.m. Eastern Time NEW YORK , July 1, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it will hold a mid-year corporate update to discuss recent positive developments in the NurOwn® program on Monday, July 8, at 8:00 a.m.
- 07/01/2024
|
BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering
- NEW YORK , June 27, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) (the "Company"), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has entered into a securities purchase agreement with a single institutional investor (the "Holder") for the purchase and sale of 11,111,111 shares of the Company's common stock (or prefunded warrants in lieu thereof) at a purchase price of $0.36 per share in a registered direct offering. In a concurrent private placement, the Company has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 16,666,667 shares of its common stock.
- 06/27/2024
|
BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial
- NEW YORK , June 26, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced it has reached alignment with the U.S. Food and Drug Administration (FDA) on the Chemistry, Manufacturing, and Controls (CMC) aspects of Brainstorm's Phase 3b clinical trial for NurOwn®, its investigational therapy for amyotrophic lateral sclerosis (ALS). This Type C meeting builds upon the positive momentum established in April 2024, when the FDA granted BrainStorm a Special Protocol Assessment (SPA) agreement for its NurOwn Phase 3b trial.
- 06/26/2024
|
BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer
- Appointment Completes Executive Readiness for Registrational Phase 3b ALS Study Launch NEW YORK , June 20, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the appointment of Hartoun Hartounian Ph.D. as its new EVP and COO, effective as of June 18, 2024.
- 06/20/2024
|
BCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn® Clinical Effectiveness Expectation
- FROM ACF EQUITY RESEARCH HEALTHCARE TEAM NASDAQ: BCLI READ ACF EQUITY RESEARCH'S INITIATION NOTE HERE READ ACF EQUITY RESEARCH'S RELATED THEMATIC RESEARCH NOTE ON REGENERATIVE MEDICINE – NEURODEGENERATIVE DISEASE STEM CELLS & ALS/MND/LOU GEHRIG'S HERE LONDON , June 14, 2024 /PRNewswire/ -- INITIATION NOTE: BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI) is focused on developing autologous mesenchymal stem cell (MSC) therapies for the treatment of neurodegenerative diseases (NDDs) – BCLI's primary target is the fatal amyotrophic lateral sclerosis (ALS/MND/Lou Gehrig's). Post hoc analysis of BCLI's PIII trial data shows BCLI's NurOwn® (debamestrocel, MSC-NTF), has statistically significant clinical effects on early-stage ALS sufferers and that placebo trialists deteriorate faster.
- 06/14/2024
|
BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwn
- The data will be presented at the Annual ALS Drug Development Summit, which is focused on identifying transformative ALS targets, seeking translational biomarkers and propelling more clinical approvals NEW YORK , May 20, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, will present new biomarker data suggesting that ALS patients may benefit from longer-term treatment with debamestrocel (NurOwn®). The Company will share the data with an international audience of patient advocacy groups, physicians, research organizations, industry representatives, key thought leaders and decision makers dedicated to ALS research at The 3rd Annual ALS Drug Development Summit, to take place May 21 to 23, 2024 in Boston MA.
- 05/20/2024
|
BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
- Company received written agreement from the U.S. FDA under a Special Protocol Assessment (SPA) on the design for a Phase 3b trial of NurOwn® Conference call planned for later this quarter to provide update on NurOwn program NEW YORK , May 14, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the First Quarter ended March 31, 2024 and provided a corporate update. "We recently achieved an important milestone on our Debamestrocel (NurOwn®) development program, reaching agreement with the US FDA on a Special Protocol Assessment for our planned Phase 3b trial of NurOwn.
- 05/14/2024
|
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
- Bob Dagher, MD, Promoted to Chief Medical Officer Dr. Stacy Lindborg Stepping Down as Co-CEO and Transitioning to Board of Directors NEW YORK , April 16, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the promotion of Dr. Bob Dagher to Executive Vice President and Chief Medical Officer. In addition, after four years of maintaining top executive roles, Dr. Stacy Lindborg stepping down from the role of Co-CEO and will remain with BrainStorm as a member of its Board of Directors.
- 04/16/2024
|
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule
- NEW YORK , April 11, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI, "the Company"), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it received a notification letter (the "Notification Letter on Compliance") on April 10, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq"), indicating that the Company has regained compliance with the minimum market value of listed securities requirement set forth under Nasdaq Listing Rule 5550(b)(2) (the "Rule"). According to the Notification Letter on Compliance, Nasdaq's staff has determined that for the 11 consecutive business days, from March 22, 2024 through April 9, 2024, the Company's market value of listed securities has been $35,000,000 or greater, and the Company has regained compliance with the Rule.
- 04/11/2024
|
BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS
- NurOwn treatment resulted in a positive impact on important CSF biomarkers relevant to ALS compared to placebo.Significant changes in multiple ALS disease pathways support NurOwn's mechanism of action and complement clinical effects observed in ALS. NEW YORK , April 10, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the peer-reviewed publication of Phase 3 biomarker data in Muscle and Nerve.
- 04/10/2024
|
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
- Conference call and webcast at 8:00 a.m. Eastern Time today NEW YORK , April 9, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it received written agreement from the U.S. Food and Drug Administration (FDA), under a Special Protocol Assessment (SPA), on the design for a Phase 3b trial of NurOwn® in amyotrophic lateral sclerosis (ALS).
- 04/09/2024
|
BrainStorm Cell Therapeutics to Provide Update on NurOwn Program
- A conference call and webcast will be held Tomorrow, April 9, at 8:00 a.m. Eastern Time NEW YORK , April 8, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call to update shareholders on the NurOwn® program tomorrow, April 9, at 8:00 AM Eastern Time.
- 04/08/2024
|
BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update
- Conference call planned for early April 2024 to provide update on NurOwn program NEW YORK , April 1, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the full year ended December 31, 2023 and provided a corporate update. "Brainstorm's priority for 2024 is to move forward with a confirmatory Phase 3b trial for NurOwn that will potentially support a new Biologics License Application," said Chaim Lebovits, President and Chief Executive Officer of BrainStorm.
- 04/01/2024
|
BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conference
- Planned Phase 3b trial Designed to Confirm Efficacy and Safety of NurOwn in mild-to-moderate ALS patients NEW YORK , Feb. 27, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will present a poster (#M201) outlining the proposed design for a Phase 3b trial of NurOwn® in amyotrophic lateral sclerosis (ALS) at the MDA Clinical and Scientific Conference, on Monday, March 4 between 6-8 p.m. at the Hilton Orlando Hotel, Florida.
- 02/27/2024
|
BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS
- NEW YORK , Feb. 23, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has submitted a Special Protocol Assessment (SPA) request to the U.S. Food and Drug Administration (FDA) for a Phase 3b study of NurOwn®, its investigational treatment for amyotrophic lateral sclerosis (ALS). The submission follows an in-person meeting that BrainStorm held with the FDA in December 2023.
- 02/23/2024
|
BrainStorm Cell Therapeutics to Present at European Life Sciences CEO Forum
- NEW YORK , Feb. 13, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will provide a corporate update at the 17th Annual European Life Sciences CEO Forum to take place 28 - 29 of February, 2024 in Zurich, Switzerland. Presentation Details Presentation Date: Wednesday, 28th FebruaryTime: 13:40h CETLocation: Panorama Room (Track C), Hilton Zurich Airport Hotel Dr. Stacy Lindborg, Co-CEO of BrainStorm, will also participate in a panel discussion Neuro Advances Panel: Highlighting the Main Opportunities, at 17:20h on February 28.
- 02/13/2024
|
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc.(BCLI) Investors of a Class Action Lawsuit and Upcoming Deadline
- NEW YORK , Jan. 2, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell" or the "Company") (NASDAQ: BCLI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Brainstorm Cell investors who were adversely affected by alleged securities fraud between August 15, 2022 and September 27, 2023.
- 01/02/2024
|
BCLI FINAL DEADLINE NOTICE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses in Excess of $500K to Secure Counsel Before Important January 2 Deadline in Securities Class Action Filed by the Firm
- NEW YORK--(BUSINESS WIRE)---- $BCLI #BCLI--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) between August 15, 2022 and September 27, 2023, both dates inclusive (the “Class Period”), of the important January 2, 2024 lead plaintiff deadline in the securities class action commenced by the Firm. SO WHAT: If you purchased Brainstorm Cell securities during the Class Period you may be entitled to compensation without paym.
- 12/31/2023
|
BCLI FINAL DEADLINE TUESDAY: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses in Excess of $500K to Secure Counsel Before Important January 2 Deadline in Securities Class Action Filed by the Firm - BCLI
- NEW YORK , Dec. 30, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) between August 15, 2022 and September 27, 2023, both dates inclusive (the "Class Period"), of the important January 2, 2024 lead plaintiff deadline in the securities class action commenced by the Firm. SO WHAT: If you purchased Brainstorm Cell securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 12/30/2023
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLI
- NEW YORK , Dec. 28, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or the "Company") (NASDAQ: BCLI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 12/28/2023
|
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Brainstorm Cell Therapeutics Inc. (BCLI)
- LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming January 2, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Brainstorm Cell Therapeutics Inc. (“Brainstorm Cell” or the “Company”) (NASDAQ: BCLI) securities between August 15, 2022 and September 27, 2023, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On November 10, 2022, Brainstorm.
- 12/28/2023
|
BRAINSTORM INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Brainstorm To Contact Him Directly To Discuss Their Options
- If you suffered losses exceeding $25,000 investing in Brainstorm securities between August 15, 2022 and September 27, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/BCLI.
- 12/28/2023
|
BCLI Investors Have Opportunity to Lead Brainstorm Cell Therapeutics Inc. Securities Fraud Lawsuit
- LOS ANGELES , Dec. 27, 2023 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell" or the "Company") (NASDAQ: BCLI).
- 12/27/2023
|
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc.(BCLI) Investors of a Class Action Lawsuit and Upcoming Deadline
- NEW YORK , Dec. 27, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Brainstorm Cell Therapeutics Inc. ("Brainstorm Cell" or the "Company") (NASDAQ: BCLI) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Brainstorm Cell investors who were adversely affected by alleged securities fraud between August 15, 2022 and September 27, 2023.
- 12/27/2023
|
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Brainstorm Cell Therapeutics Inc. with Losses of $100,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / December 26, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Brainstorm Cell Therapeutics Inc. ("BrainStorm" or "the Company") (NASDAQ:BCLI) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 15, 2022 and September 27, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before January 2, 2024.
- 12/26/2023
|
BrainStorm Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder Treatments
- NEW YORK , Dec. 26, 2023 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today provided an update on the grant and allowance of three patent applications for NurOwn® and NurOwn-Exosomes. The European Patent office granted patent No.
- 12/26/2023
|
BrainStorm Cell Therapeutics to Present at 6th Annual ALS Research Symposia
- Presentation on NurOwn Phase 3 data demonstrating evidence of biological effect in ALS; Biomarker data reinforce clinical outcomes NEW YORK , Nov. 17, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced a podium presentation and panel discussion at the 6th Annual ALS Research Symposium hosted by ALS ONE. The presentation will feature new analyses from the NurOwn placebo-controlled Phase 3 amyotrophic lateral sclerosis (ALS) trial that highlight the biological effect of NurOwn through CSF biomarker data.
- 11/17/2023
|
BrainStorm Cell Therapeutics Inc. (BCLI) Q3 2023 Earnings Call Transcript
- Start Time: 08:30 January 1, 0000 8:58 AM ET BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI ) Q3 2023 Earnings Conference Call November 14, 2023, 08:30 AM ET Company Participants Chaim Lebovits - President and CEO Stacy Lindborg - Co-CEO Alla Patlis - Interim CFO Michael Wood - LifeSci Advisors Conference Call Participants David Bautz - Zacks Small-Cap Research Operator Greetings, and welcome to the BrainStorm Cell Therapeutics Third Quarter 2023 Earnings Call. At this time, participants are in a listen-only mode.
- 11/14/2023
|
BrainStorm shares plunge 56% after FDA advisers reject ALS cell therapy
- Shares of BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) plummeted by 56% in early trading after the company's treatment for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, received the red light from advisors to the US Food and Drug Administration (FDA). The Cellular, Tissue, and Gene Therapies Advisory Committee voted 17 to 1, with one abstention, against the efficacy of BrainStorm's cell therapy, NurOwn.
- 09/28/2023
|
Brainstorm Cell Therapeutics shares fall more than 50% after FDA advisors vote down ALS treatment
- BrainStorm Cell Therapeutics Inc. BCLI, -8.35% shares fell 56% premarket on Thursday after advisors to the U.S. Food and Drug Administration on Wednesday gave a thumbs-down to the company's investigational treatment for amyotrophic lateral sclerosis (ALS). The FDA advisors voted that the treatment, the mesenchymal stem cell therapy NurOwn, did not demonstrate substantial evidence of effectiveness for treatment of mild to moderate ALS.
- 09/28/2023
|
FDA panel rejects ALS treatment from Brainstorm Cell Therapeutics
- A U.S. Food and Drug Administration advisory committee voted against a treatment from BrainStorm Cell Therapeutics BCLI, -8.35% for amyotrophic lateral sclerosis, or ALS.
- 09/27/2023
|
US FDA panel votes against BrainStorm's ALS therapy
- The U.S. health regulator's advisers on Wednesday voted against BrainStorm Cell Therapeutics' therapy for patients with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease.
- 09/27/2023
|
BrainStorm Cell shares fall as FDA reviewers raise doubts over effectiveness of ASL therapy
- Shares of BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) fell almost 40% on Monday morning after Food and Drug Administration (FDA) staff reviewers expressed doubts over the safety and efficacy of the biotech's therapy NurOwn for neurogenerative disease amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. Brainstorm's NurOwn is being reviewed by the FDA's Cellular, Tissue and Gene Therapies Advisory Committee on Wednesday, September 2023.
- 09/25/2023
|
FDA staff reviewers raise concerns over BrainStorm Cell's ALS therapy
- The U.S. Food and Drug Administration's staff reviewers raised concerns on Monday over the safety and efficacy of BrainStorm Cell Therapeutics' amyotrophic lateral sclerosis (ALS) therapy, sending the company's shares down 50% in premarket trading.
- 09/25/2023
|
Brainstorm Cell Therapeutics: I Anticipate A Positive AdCom But There Are Major Risks
- BCLI has completed a phase 3 trial in ALS. Despite not meeting the primary endpoint BCLI is still applying for approval and an AdCom meeting is scheduled for September 27. NurOwn was significantly better than placebo in the pre-specified subgroup of patients with earlier-stage ALS as well as in post-hoc analyses accounting for the "floor effect". Supportive biomarker data and Fast Track designation mean potential for accelerated approval (similar to the recently approved tofersen, which also did not meet the primary endpoint in its phase 3).
- 09/15/2023
|
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Quarter - Brainstorm Cell (NASDAQ:BCLI), Cosmos Health (NASDAQ:COSM)
- The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
- 07/27/2023
|
BrainStorm to Announce First Quarter 2023 Financial Results and Provide a Corporate Update
- NEW YORK , May 9, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call to update shareholders on financial results for the First Quarter ended March 31, 2023, and provide a corporate update, at 8:00 a.m. Eastern Time on Monday, May 15th.
- 05/09/2023
|
BrainStorm to Announce Fourth Quarter and Fiscal Year 2022 Financial Results and Provide a Corporate Update
- NEW YORK , March 21, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call to update shareholders on financial results for the fourth quarter and year ended December 31, 2022, and provide a corporate update, at 8:00 a.m. Eastern Time on Thursday, March 30th.
- 03/21/2023
|
BrainStorm Cell Therapeutics to Announce Third Quarter Results and Provide a Corporate Update
- NEW YORK , Nov. 7, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will hold a conference call to update shareholders on financial results for the third quarter ended September 30, 2022, and provide a corporate update, at 8:00 a.m. Eastern Time on Monday, November 14, 2022.
- 11/07/2022
|
Brainstorm Cell Therapeutics: Upcoming BLA In ALS
- Brainstorm Cell Therapeutics is a company developing NurOwn as an autologous stem cell-based treatment for ALS and MS. NurOwn's mechanism of action relies on bringing down neuroinflammation and altering glial activity, a recipe that seems to be a winner in neurodegenerative diseases.
- 08/21/2022
|
BrainStorm to Announce Second Quarter Results and Provide a Corporate Update
- NEW YORK , Aug. 1, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call to update shareholders on financial results for the second quarter, ended on June 30, 2022, and provide a corporate update, at 8:00 a.m. Eastern Time on Monday, August 15, 2022.
- 08/01/2022
|
Brainstorm Cell Therapeutics Inc.'s (BCLI) CEO Chaim Lebovits on Q1 2022 Results - Earnings Call Transcript
- Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI ) Q1 2022 Earnings Conference Call May 16, 2022 8:00 AM ET Company Participants Tom Galassi - Investor Relations, LifeSci Advisors Chaim Lebovits - Chief Executive Officer Alla Patlis - Interim Chief Financial Officer Stacy Lindborg - Executive Vice President and Chief Development Officer Ralph Kern - President and Chief Medical Officer David Setboun - Executive Vice President and Chief Operating Officer Conference Call Participants David Bautz - Zacks Small-Cap Research Michelle Lorenz - Voices for ALS Operator Greetings and welcome to the Brainstorm Cell Therapeutics First Quarter 2022 Conference Call. At this time, participants are in a listen-only mode.
- 05/16/2022
|
BrainStorm to Announce First Quarter 2022 Financial Results and Provide a Corporate Update
- NEW YORK , May 2, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will hold a conference call to update shareholders on financial results for the first quarter ended March 31, 2022, and provide a corporate update, at 8:00 a.m. Eastern Time on May 16, 2022.
- 05/02/2022
|
BrainStorm Cell Therapeutics Inc. (BCLI) CEO Chaim Lebovits on Q4 2021 Results - Earnings Call Transcript
- BrainStorm Cell Therapeutics Inc. (BCLI) CEO Chaim Lebovits on Q4 2021 Results - Earnings Call Transcript
- 03/28/2022
|
BrainStorm to Announce Fourth Quarter and Fiscal Year 2021 Financial Results and Provide a Corporate Update
- NEW YORK, March 14, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will hold a conference call to update shareholders on financial results for the fourth quarter and year ended December 31, 2021, and provide a corporate update, at 8:00 a.m. Eastern Time on Monday, March 28, 2022.
- 03/14/2022
|
BrainStorm Cell Therapeutics to Present at the 12th Annual California ALS Research Summit
- NEW YORK, Jan. 27, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Ralph Kern, M.D., MHSc, President and Chief Medical Officer of BrainStorm Cell Therapeutics, will provide a corporate and clinical overview at the 12th Annual California ALS Research Summit, which is being held virtually January 27-28, 2022.
- 01/27/2022
|
BrainStorm Cell Therapeutics to Present at Biotech Showcase™ 2022
- NEW YORK, Jan. 4, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Ralph Kern, M.D. MHSc, President and Chief Medical Officer of Brainstorm Cell Therapeutics, will provide a corporate and clinical overview at Biotech Showcase™ 2022, to be held virtually January 10-12 and 17-18, 2022.
- 01/04/2022
|
Brainstorm Cell Therapeutics Inc. (BCLI) CEO Chaim Lebovits on Q3 2021 Results - Earnings Call Transcript
- Brainstorm Cell Therapeutics Inc. (BCLI) CEO Chaim Lebovits on Q3 2021 Results - Earnings Call Transcript
- 11/15/2021
|
BrainStorm Announces Scientific Presentation of NurOwn® Exosome Preclinical ARDS Data at NYSCF 2021 VIRTUAL Meeting
- NEW YORK, Oct. 18, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of a poster titled, "Therapeutic Benefits of MSC-NTF (NurOwn®) Exosomes in Acute Lung Injury Models" at the NYSCF 2021 VIRTUAL Meeting, being held on October 19-20, 2021. The poster will be presented tomorrow, October 19, at 3:45 – 5:00pm Eastern Time.
- 10/18/2021
|
Phase 2 Clinical Trial Data of NurOwn® in Progressive MS Will Be Presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
- NEW YORK, Oct. 14, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, will present findings from a multicenter, open label clinical trial of NurOwn® in progressive multiple sclerosis. The study, "Phase 2 Safety and Efficacy Study of Intrathecal MSC-NTF cells in Progressive Multiple Sclerosis," will be delivered in an oral presentation today at the fully digital 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
- 10/14/2021
|
BrainStorm to Present ALS Phase 3 Biomarker Analyses at Annual NEALS Meeting October 6th, 2021
- NEW YORK, Oct. 6, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that a scientific abstract titled "CSF biomarker correlations with primary outcome in NurOwn Phase 3 clinical trial" will be presented as a scientific poster at the fully digital 2021 Northeast Amyotrophic Lateral Sclerosis Consortium® (NEALS) conference. The presentation will be delivered by James Berry, M.D.
- 10/06/2021
|
BrainStorm to Present at the 2021 Cell & Gene Meeting on the Mesa
- NEW YORK, Oct. 4, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that Stacy Lindborg, Ph.D., Executive Vice President and Head of Global Clinical Research, will deliver a presentation at the 2021 Cell & Gene Meeting on the Mesa, being held as a hybrid conference October 12-14, and October 19-20, 2021.
- 10/04/2021
|
BrainStorm to Present Phase 2 Progressive MS Study Results in Oral Presentation at 37th Congress of ECTRIMS
- NEW YORK, Oct. 1, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that a scientific abstract titled "Phase 2 Safety and Efficacy Study of Intrathecal MSC-NTF cells in Progressive Multiple Sclerosis" will be presented in an oral presentation at the fully digital 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The presentation will be delivered by Jeffrey Cohen, M.D.
- 10/01/2021
|
BrainStorm Cell Therapeutics Inc. (BCLI) CEO Chaim Lebovits on Q2 2021 Results - Earnings Call Transcript
- BrainStorm Cell Therapeutics Inc. (BCLI) CEO Chaim Lebovits on Q2 2021 Results - Earnings Call Transcript
- 08/05/2021
|
BrainStorm Increases Commercial Manufacturing Capacity; Granted GMP Certification for a Second Production Site in Israel
- NEW YORK, July 27, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that is has received Good Manufacturing Practice (GMP) approval from the Israel Ministry of Health for three state-of-the-art cleanrooms leased by the Company at the Tel Aviv Sourasky Medical Center ("Sourasky Hospital") in Tel Aviv, Israel. The GMP approval confirms that these cleanrooms are compliant with Israeli GMPs, which are aligned with European Union (EU) GMPs, and more than doubles the Company's capacity to manufacture and ship NurOwn® into the EU and local Israeli markets.
- 07/27/2021
|
BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update
- NEW YORK, July 26, 2021 /PRNewswire/ --BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will hold a conference call to update shareholders on financial results for the second quarter ended June 30, 2021, and provide a corporate update, at 8:00 a.m. Eastern Time on August 05, 2021.
- 07/26/2021
|
Brainstorm Announces Expansion of NurOwn® IP Portfolio with Grant and Allowance of Multiple Patents and Applications in Major Markets
- NEW YORK, June 15, 2021 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the grant and/or allowance of a series of patents and patent applications. These patents and patent applications, which were granted/allowed in 2020 and 2021, are expected to provide broad protection for Brainstorm's proprietary NurOwn® (MSC-NTF cells) technology in territories including the U.S., E.U.
- 06/15/2021
|
Brainstorm Cell Therapeutics: MSC-NTF Cell Therapy Shows Mid-Stage Promise In PMS
- Brainstorm Cell Therapeutics, Inc. is a biotechnology company developing best-in-class autologous cell therapies for treating neurodegenerative diseases including ALS, PMS, Alzheimer's, and others. Brainstorm's modified mesenchymal stem cells are being tested in one ongoing Phase 2 trial for PMS (promising top-line data) and one soon-to-be-initiated Phase 2 trial for Alzheimer's.
- 05/30/2021
|
BrainStorm Announces Scientific Presentation of NurOwn® Exosome Preclinical ARDS Data at ISCT 2021 New Orleans VIRTUAL Meeting
- NEW YORK, May 25, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of a poster titled, "Molecular Mechanisms Underlying MSC-NTF (NurOwn®) Exosome Benefits in a Mouse LPS-induced ARDS Model" at the ISCT 2021 New Orleans VIRTUAL Meeting, being held from May 25-28, 2021. The poster will be presented during Virtual Poster Hall Session 2: May 25, 20:00-21:30 EDT.
- 05/25/2021
|
BrainStorm Cell Therapeutics Inc. (BCLI) CEO Chaim Lebovits on Q1 2021 Results - Earnings Call Transcript
- BrainStorm Cell Therapeutics Inc. (BCLI) CEO Chaim Lebovits on Q1 2021 Results - Earnings Call Transcript
- 04/26/2021
|
BrainStorm Announces First Quarter 2021 Financial Results and Provides a Corporate Update
- NEW YORK, April 26, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for the first quarter ended March 31, 2021 and provided a corporate update. "In the first quarter we were excited to announce positive top line data from our Phase 2 trial evaluating NurOwn ® as a treatment for progressive multiple sclerosis (MS).
- 04/26/2021
|
BrainStorm to Announce First Quarter Financial Results and Provide a Corporate Update
- NEW YORK, April 19, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will hold a conference call to update shareholders on financial results for the first quarter ended March 31, 2021, and provide a corporate update, at 8:00 a.m. Eastern Time on April 26, 2021.
- 04/19/2021
|
BCLI Stock Price Increases Over 25% Pre-Market: Why It Happened
- The stock price of Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI) increased by over 25% pre-market. This is why it happened.
- 03/24/2021
|
BrainStorm Announces Positive Topline Data in Phase 2 Study Evaluating NurOwn® as a Treatment for Progressive MS
- NEW YORK, March 24, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today topline data from the Company's Phase 2 trial evaluating three repeated administrations of NurOwn® (MSC-NTF cells), each given 2 months apart, as a treatment for progressive multiple sclerosis (MS). The study achieved the primary endpoint of safety and improvements were observed in secondary endpoints spanning neurologic function, cognition, and biomarkers.
- 03/24/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLI
- New York, New York--(Newsfile Corp. - March 7, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or the "Company") (NASDAQ: BCLI). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.The investigation concerns whether Brainstorm and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about...
- 03/07/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLI
- NEW YORK, March 3, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or the "Company") (NASDAQ: BCLI). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529,...
- 03/03/2021
|
Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Brainstorm Cell Therapeutics Inc. (BCLI) Investigation
- NEW YORK--(BUSINESS WIRE)--Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or "the Company") (NASDAQ: BCLI). Investors who purchased Brainstorm securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/bcli. The investigation concerns whether Brainstorm and certain of its officers and/or directors hav
- 02/24/2021
|
BrainStorm Announces High-Level FDA Feedback on NurOwn® ALS Clinical Development Program
- NEW YORK, Feb. 22, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it recently met with senior leadership from the U.S. Food and Drug Administration (FDA) and...
- 02/22/2021
|
Longeveron Seeks $25 Million IPO For Anti-Aging Efforts
- Longeveron Seeks $25 Million IPO For Anti-Aging Efforts
- 02/05/2021
|
Why Infinity Pharma, Meridian Bio, More Biotech Stocks Are Moving Today
- Infinity Pharmaceuticals (NASDAQ: INFI) shares are trading higher Friday after JPMorgan upgraded the stock from Underweight to Neutral. Infinity Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel medicines for the treatment of specific cancers.
- 02/05/2021
|
Why BrainStorm Cell Therapeutics Blasted 27.7% Higher Today
- The company isn't giving up on a promising pipeline drug.
- 02/04/2021
|
Brainstorm Cell Therapeutics Inc.'s (BCLI) CEO Chaim Lebovits on Q4 2020 Results - Earnings Call Transcript
- Brainstorm Cell Therapeutics Inc.'s (BCLI) CEO Chaim Lebovits on Q4 2020 Results - Earnings Call Transcript
- 02/04/2021
|
BrainStorm Announces the Publication of Preclinical Data Highlighting the Potential of a NurOwn® Derived Exosome-Based Treatment for COVID-19 ARDS
- NEW YORK, Jan. 20, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today the peer-reviewed publication of a preclinical study in the journal Stem Cell and Research Therapy....
- 01/20/2021
|
BrainStorm Issues 2020 Letter to Shareholders
- NEW YORK, Dec. 28, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the following letter from its Chief Executive Officer, Chaim Lebovits, to its shareholders and the investment...
- 12/28/2020
|
BrainStorm Announces Completion of All Dosing in NurOwn® Phase 2 MS Study
- NEW YORK, Dec. 18, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that all dosing has been completed in the ongoing Phase 2 trial evaluating NurOwn® (MSC-NTF cells) as...
- 12/18/2020
|
Hedge Funds Aren't Crazy About Brainstorm Cell Therapeutics Inc. (BCLI) Anymore
- Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out what the billionaire investors and hedge funds think of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI).
- 11/26/2020
|
Brainstorm Cell Therapeutics News: 8 Things for BCLI Stock Investors to Know About the ALS Study
- Brainstorm Cell Therapeutics (BCLI) news for Tuesday has BCLI stock taking a beating following results from its ALS study. The post Brainstorm Cell Therapeutics News: 8 Things for BCLI Stock Investors to Know About the ALS Study appeared first on InvestorPlace.
- 11/17/2020
|
Why BrainStorm Cell Therapeutics Stock Imploded Today
- The company reported disappointing results from a pivotal clinical trial.
- 11/17/2020
|
BrainStorm Announces Topline Results from NurOwn® Phase 3 ALS Study
- NEW YORK, Nov. 17, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today topline results from the Company's randomized, double-blind placebo-controlled Phase 3 trial...
- 11/17/2020
|
Global Flow Batteries Market Trajectory & Analytics 2020-2027: Market to Gain from Novel Research Programs and Technology Improvements - ResearchAndMarkets.com
|
The Daily Biotech Pulse: Vertex Pulls Plug On Protein Deficiency Drug, FDA Nod For Regeneron's Ebola Treatment, Can Fite Issues Psoriasis Readout
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 14)
10X Genomics Inc (NASDAQ:...
- 10/15/2020
|
PlusDental expandiert nach Frankreich und ist Deutschlands Testsieger
- Plusdental expandiert im Rahmen seines Wachstumskurses in den französischen Markt und ist nun in insgesamt sechs europäischen Ländern vertreten. Das B
- 10/08/2020
|
Sabio Group erweitert mit der Übernahme von Anana ihre Kompetenzen in Kundenerfahrung
- Sabio Group hat den Spezialisten für Kundenerfahrungslösungen Anana erworben. Die Übernahme unterstützt das Ziel von Sabio, zum führenden Anbieter auf
- 10/06/2020
|
Automotive Testing, Inspection, And Certification Market by Type (in-house and outsourced) and Geography (Europe, North America, APAC, MEA, and South America)|COVID-19 Impact Analysis
- The Global TIC Market will grow by USD 4.43 bn during 2020-2024
- 09/30/2020
|
Team Gleason Donates $750,000 To Expand Boston Children’s Hospital’s ALS Augmentative Communication Program. This Five-year Collaboration Will Provide Services to People With ALS Across the Country.
- Team Gleason is collaborating with Boston Children’s Hospital’s ALS Augmentative Communication Program to provide voice banking and message banking.
- 09/29/2020
|
16,310 Shares in Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) Acquired by American International Group Inc.
- American International Group Inc. purchased a new position in Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) during the 2nd quarter, HoldingsChannel reports. The firm purchased 16,310 shares of the biotechnology company’s stock, valued at approximately $183,000. Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Ameritas Investment Partners […]
- 09/24/2020
|
Food Safety Testing Market by Contaminant, Technology, and Food Tested - Global Forecast to 2027 - ResearchAndMarkets.com
|
Sir Richard Branson ist Hauptredner neben Dr. Anthony Fauci und Dr. Sanjay Gupta beim virtuellen Symposium von Everbridge, „COVID-19: Road to Recovery (R2R)“, am 14. und 15. Oktober 2020
- Everbridge, Inc. (NASDAQ: EVBG), der weltweit führende Anbieter im Bereich Critical Event Management (CEM), teilte heute mit, dass das Programm des vi
- 09/15/2020
|
BrainStorm Announces Publication of New Preclinical Data Supporting Proposed NurOwn® Mechanism in ALS, Progressive MS and Alzheimer's Disease
- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today the publication of a manuscript titled, "Effects of MSC-NTF cells on T and B regulatory cell function in ALS" in the journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration.
- 08/19/2020
|
Arizona Metals Corp Announces Drilling at its Sugarloaf Peak Heap-leach Gold-oxide Project in La Paz County, Arizona Intersects 137 m of 0.53 g/t Gold From Surface, Including 99 m of 0.62 g/t Gold, and 30 m of 0.90 g/t Gold.
- Arizona Metals Corp. (TSX.V:AMC, OTCQB:AZMCF) (the “Company” or “Arizona Metals”) is pleased to announce the first drill hole from its recently comple
- 08/11/2020
|
We're Keeping An Eye On Brainstorm Cell Therapeutics' (NASDAQ:BCLI) Cash Burn Rate
- Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- 08/10/2020
|
BrainStorm to Present at the 40th Annual Canaccord Genuity Growth Conference
- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Ralph Kern, MD, MHSc, President and Chief Medical Officer, will present a corporate overview during the 40th Annual Canaccord Genuity Growth Conference, to be held virtually August 11-13, 2020. Company management will also be available for 1on1 meetings with institutional investors via video conference on the day of the presentation. To request a meeting, please contact your representative at Canaccord Genuity.
- 08/10/2020
|
Evogene Ltd. (EVGN) CEO Ofer Haviv on Q2 2020 Results - Earnings Call Transcript
- Evogene Ltd. (NASDAQ:EVGN) Q2 2020 Earnings Conference Call August 5, 2020 09:00 ET Company Participants Ofer Haviv - Chief Executive Officer Dorit Kreiner - Chief Financial Officer Gadi Ben Nissim - Executive Vice President, Corporate Development Presentation Operator Ladies and gentlemen, thank you for standing by.
- 08/10/2020
|
BCLI: Phase 3 ALS Data Expected by the End of November 2020…
- By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Topline Data from Phase 3 ALS Trial Before End of November 2020 BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) is currently conducting a Phase 3 clinical trial of NurOwn® in patients with amyotrophic lateral sclerosis (ALS) ( NCT03280056 ). A total of 200 patients were randomized 1:1 to receive NurOwn® or placebo
- 08/07/2020
|
BrainStorm Announces Financial Results for the Second Quarter of 2020 and Provides a Corporate Update
- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for the second quarter and first half ended June 30, 2020, and provided a corporate update.
- 08/05/2020
|
The Daily Biotech Pulse: Novavax Vaccine Data, Aerpio Gets $5.1M Funding For COVID Trial, Rigel Gains Big On Earnings
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 4)
ABIOMED, Inc. (NASDAQ: ABMD) (FDA approved the emergency use of Abiomed's Impella heart pump in combination...
- 08/05/2020
|
Conformance Technologies Deepens Relationship with InfoSecure Redteam
- InfoSecure Redteam becomes Conformance Cybersecurity to expedite strategic market penetration of products and services via Conformance Technologies.
- 08/04/2020
|
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
- Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.
COVID-19 news flow continued to pour in,...
- 08/02/2020
|
BrainStorm Cell Therapeutics to Announce Second Quarter Financial Results and Provide a Corporate and R&D Update
- BrainStorm-Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that the Company will hold a conference call to update shareholders on financial results for the second quarter ended June 30, 2020, and provide a corporate update, at 8:00 a.m., Eastern Daylight Time (EDT), on Wednesday, August 5 2020.
- 07/27/2020
|
The Daily Biotech Pulse: Mixed Tidings From Novavax, Radius Health Out-licenses Breast Cancer Drug, 3 IPOs
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 23)
Abbott Laboratories (NYSE: ABT)
ABIOMED, Inc. (NASDAQ: ABMD)
Acceleron Pharma Inc (NASDAQ: XLRN)
Aerpio...
- 07/24/2020
|
5 Stock Gainers for Thursday: Smith & Wesson, Calix, Sunopta
- Smith & Wesson Brands, Calix, Sunopta, eXp Realty, and Vivent Solar are some of Thursday's movers.
- 07/23/2020
|
Longtime IIA CEO Richard Chambers plans to step down in March
- Richard Chambers, who has led the Institute of Internal Auditors for 12 years, will be stepping down effective March 31, 2021. The IIA plans to begin an immediate search for a new CEO.
- 07/23/2020
|
BrainStorm Announces Groundbreaking Pre-Clinical Study of NurOwn® derived Exosome-Based Treatment for COVID-19 ARDS
- Graph A quantitative analysis for Acute Lung Injury was performed using a severity scoring scale, showed a significant reduction in the severity of lung injury in Nurown exosomes group as compare to control treated group. Image Representative histologic photographs of lungs in LPS-induced lung injury, treated by MSC or Nurown exosomes. (hematoxylin and eosin staining; magnification, ×10)Intratracheal administration of exosomes extracted from MSC’s using NurOwn® technology resulted in statistically significant improvement in multiple lung parameters in a mouse model BrainStorm will discuss results during Q2 corporate earnings call on Wednesday August 5NEW YORK, July 23, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it has successfully completed its first milestone in developing an innovative exosome-based platform-technology for the treatment severe COVID-19 infection.COVID-19 induced pneumonia carries a high fatality rate and has been associated with acute respiratory distress syndrome (ARDS). Currently, there is no effective treatment strategy to prevent or reverse ARDS, a type of respiratory failure associated with widespread inflammation and lung damage mediated by dysregulated cytokine production. Exosomes are nano-sized (30–150 nm) vesicles secreted by all cell types. Mesenchymal stem cells (MSC) derived exosomes have been suggested as a potential treatment for ARDS due to their ability to penetrate into deep tissues, effectively deliver bioactive molecules to target cells and mitigate the inflammatory response. MSC exosomes may be delivered intravenously or directly into the lung via intratracheal administration. Results from a study in a mouse model of lipopolysaccharide (LPS)-induced ARDS showed that intratracheal administration of NurOwn® (MSC-NTF cells) derived exosomes resulted in a statistically significant improvement in multiple lung parameters. These included the clinically relevant factors: functional lung recovery, reduction in pro-inflammatory cytokines and most importantly, attenuation of lung damage. Moreover, MSC-NTF cell derived exosomes exhibited a superior effect when compared to treatment with exosomes derived from naïve mesenchymal stem cells (MSC) from the same donor. BrainStorm intends to accelerate submission of these important results to peer-reviewed medical journals. The preclinical experiment demonstrated a statistically significant reduction in lung disease severity score (p=0.03) (based on the American Thoracic Society Documents, 2011; Matute-Bello et al., Am J Respir Cell Mol Biol 44;725-738, 2011) and vastly improved lung histology following intratracheal administration of NurOwn (MSC-NTF) exosomes compared to MSC exosomes.A graph accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/224bd3d0-90a3-4850-8b56-854d808c6386An image accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e5276300-106b-4a35-9ef5-7d8907561db9To-date, BrainStorm Cell Therapeutics has focused its clinical development on the application of the NurOwn technology platform to neurodegenerative disorders. Given these important pre-clinical results, the Company will revisit its strategy to determine if and when to proceed with a clinical trial in ARDS. Dr. Revital Aricha, VP of Research & Development at BrainStorm, will discuss the results on the company’s second quarter 2020 earnings call and corporate update, scheduled for Wednesday August 5th, at 8.00am ET.About NurOwn®The NurOwn technology platform (autologous Mesenchymal stem cells, MSC-NTF cells) represent a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression.About BrainStorm Cell Therapeutics Inc.BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six U.S. sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm is also conducting a U.S. FDA approved Phase 2 open-label multicenter trial in progressive multiple sclerosis (MS). The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) started enrollment in March 2019. For more information, visit the company's website at www.brainstorm-cell.comSafe-Harbor StatementStatements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm’s need to raise additional capital, BrainStorm’s ability to continue as a going concern, regulatory approval of BrainStorm’s NurOwn treatment candidate, the success of BrainStorm’s product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm’s NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm’s ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm’s ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.CONTACTS Investor Relations: Preetam Shah, MBA, PhD Chief Financial Officer BrainStorm Cell Therapeutics Inc. Phone: + 1.862.397.1860 pshah@brainstorm-cell.comMedia:Paul Tyahla SmithSolve Phone: + 1.973.713.3768 Paul.tyahla@smithsolve.com
- 07/23/2020
|
The Daily Biotech Pulse: Aurinia's Kidney Inflammation Drug Filing Accepted For Review, Intuitive Surgical's Q2 Beat
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 21)
ABIOMED, Inc. (NASDAQ: ABMD)
Assembly Biosciences Inc (NASDAQ: ASMB)
Bio-Rad Laboratories, Inc. (NYSE: BIO)...
- 07/22/2020
|
Insider Weekends: Andrew Spodek Purchases $1 Million Worth Of Postal Realty Trust
- Insider buying increased last week. Notable Insider Buys: Postal Realty Trust, Inc., Avid Technology, Inc., Brainstorm Cell Therapeutics Inc., Perspecta Inc., and AZZ Inc.
- 07/20/2020
|
MasterCard : Invest in Africa (IIA) and the Mastercard Foundation Join Forces for the Survival of COVID-hit Companies in Ghana, Kenya and Senegal | MarketScreener
|
BCLI: KOL Event Gives Overview of the use of NurOwn® in Alzheimer’s Disease; Raising Valuation to $25/Share…
- By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update KOL Event for Alzheimer’s Program On July 8, 2020, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) conducted a Key Opinion Leader (KOL) webinar to discuss the company’s upcoming Phase 2a clinical trial of NurOwn® in patients with Alzheimer’s Disease (AD). The event included presentations by two of the lead
- 07/09/2020
|
IIA, IFAC urge audit committees to address coronavirus risks
- The Institute of Internal Auditors and the International Federation of Accountants are calling on audit committees to be vigilant about risk management, performance, controls and processes during the COVID-19 pandemic.
- 07/08/2020
|
BrainStorm Hosting KOL Webinar to Discuss NurOwn® Phase 2 Alzheimer's Disease Program
- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, is hosting a Key Opinion Leader (KOL) webinar on its Alzheimer's Disease (AD) program today at 8:15 AM Eastern Time. The Company recently announced that it is expanding its clinical pipeline to develop NurOwn® and begin a Phase 2 study in AD.
- 07/08/2020
|
Lineage Cell Therapeutics Announces Extension of OpRegen® Development Grant From Israel Innovation Authority
- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medic
- 07/06/2020
|
Stocks To Watch: Postmates, Walgreens And Cannabis Plays
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
- 07/04/2020
|
BrainStorm Announces Completion of All Dosing in NurOwn® Phase 3 Clinical Trial in ALS
- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that final participant dosing has been administered in the Phase 3 pivotal trial of NurOwn® (MSC-NTF cells) in amyotrophic lateral sclerosis (ALS). The trial enrolled approximately 200 participants, randomized 1:1 to receive three doses of MSC-NTF cells or placebo, administered over four months. As previously reported, the Company expects top-line data from the trial to be available in the fourth quarter of 2020, consistent with the timeline established upon trial enrollment.
- 07/02/2020
|
BrainStorm to Showcase Alzheimer's Disease Clinical Program in KOL Webinar
- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, will hold a Key Opinion Leader (KOL) webinar on the Company's Alzheimer's disease (AD) clinical program on Wednesday July 8th at 8.15am ET. The Company recently announced that it is expanding its clinical pipeline to develop NurOwn® in AD.
- 07/01/2020
|
Can-Fite Announces Final Data Analysis from Phase II NASH Study:
Highly Significant and Sustained Reduction in Liver Fat Volume Throughout Study Period
- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that addre
- 06/30/2020
|
Monday’s Highlights at Noon: Brainstorm Cell Therapeutics (BCLI), Heron Therapeutics (HRTX), Plug Power (PLUG), Rite Aid (RAD), Ballard Power Systems (BLDP) - Markets
- So far Monday, June 29, NASDAQ is up 3.38% and the S&P is up 2.09%. Let’s take a look at
- 06/29/2020
|
Arizona Metals Corp Announces trunk Hole KM-20-10 Intersects 4.9 m of 6.2% CuEq, as well as 0.6 m of 9.6g/t AuEq and 1.6m of 3.1% CuEQ, at its Kay Mine VMS Project in Arizona
- Arizona Metals Corp. (TSX.V:AMC) (the “Company” or “Arizona Metals”) is pleased to announce that drilling at the South Zone of its Kay Mine Project, l
- 06/29/2020
|
The Daily Biotech Pulse: Chiasma, Heron Await FDA Decisions, DBV Restructures, 3 Biopharmas Make Wall Street Debuts
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 25)
Brainstorm Cell...
- 06/26/2020
|
Maxim Group Gives a Buy Rating to Titan Pharmaceuticals (TTNP) - Markets
- Maxim Group analyst Jason McCarthy assigned a Buy rating to Titan Pharmaceuticals (TTNP – Research Report) today and set a
- 06/25/2020
|
Soligenix (SNGX) Receives a Buy from Maxim Group - Markets
- In a report released today, Jason McCarthy from Maxim Group assigned a Buy rating to Soligenix (SNGX – Research Report),
- 06/25/2020
|
The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene Therapy
- The following is a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24) * ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) * BioXcel Therapeutics Inc (NASDAQ: BTAI) * Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI) (announced new clinical program focused on the development of NurOwn as a treatment for Alzheimer's disease) * Burning Rock Biotech Ltd (NASDAQ: BNR) (went public June 12) * Cardiff Oncology Inc (NASDAQ: CRDF) * ESSA Pharma Inc (NASDAQ: EPIX) * Five Prime Therapeutics Inc (NASDAQ: FPRX) * Horizon Therapeutics PLC (NASDAQ: HZNP) * IGM Biosciences Inc (NASDAQ: IGMS) * Inovio Pharmaceuticals Inc (NASDAQ: INO) * Kamada Ltd. (NASDAQ: KMDA) * Novavax, Inc. (NASDAQ: NVAX) * Passage Bio Inc (NASDAQ: PASG) * Pliant Therapeutics Inc (NASDAQ: PLRX) * Translate Bio Inc (NASDAQ: TBIO) * Twist Bioscience Corp (NASDAQ: TWST)Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 24) * Genetron Holdings Ltd - ADR (NASDAQ: GTH) (went public Friday) * Vaccinex Inc (NASDAQ: VCNX)Stocks In Focus Merck's Keytruda Approved For Skin Cancer Merck & Co., Inc. (NYSE: MRK) said the FDA as approved Keytruda, its anti-PD-1 therapy, as monotherapy for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma that is not curable by surgery or radiation.In pre-market trading, Merck shares were down 0.65% to $75.38.UniQure Out-Licenses Investigational Late-Stage Hemophilia B Gene Therapy For Up To $2.05B Gene therapy company Uniqure NV (NASDAQ: QURE) said it has entered into a licensing agreement with CSL Behring, providing the latter with exclusive global rights to etranacogene dezaparvovec, uniQure's investigational gene therapy for patients with hemophilia B.The agreement provides for uniQure receiving a $450 million upfront cash payment and potentially up to $1.6 billion in payments based on regulatory and commercial milestones. The company is also eligible to receive tiered double-digit royalties in a range of up to a low-20s percentage of net product sales arising from the collaboration.UniQure said the proposed transaction will provide significant financial resources to advance and expand its pipeline of gene therapy candidates, anchored by AMT-130 in Huntington's disease, and to invest further in its leading gene therapy manufacturing and technology platform to support pipeline growth.The stock was down 16.39% at $52.60 premarket Thursday.La Jolla Agrees To Buy Tetraphase After protracted three-way wrangling, Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) clinched a definitive merger agreement to be bought by La Jolla Pharmaceutical Company (NASDAQ: LJPC) for $43 million in upfront cash, plus potential future cash payments of up to $16 million pursuant to contingent value rights.Melinta, which had earlier agreed to buy Tetraphase, terminated the agreement, and was paid $1.15 million as a break-up fee.In after-hours trading, Tetraphase shares declined 1.85% to $2.65, while La Jolla gained 2.08% to $4.90.See also: The Week Ahead In Biotech: Karyopharm, Zogenix, Heron, Chiasma On The Radar Ahead Of FDA Decisions Theravance Doses First Patient In Phase 2 COVID-19 Study Theravance Biopharma Inc (NASDAQ: TBPH) said the first COVID-19 patient has been dosed in a Phase 2 study of TD-0903, its lung-selective, nebulized Janus kinase inhibitor in development for the potential treatment of hospitalized patients with acute lung Injury caused by COVID-19.Offerings HUTCHISON CHINA/S ADR (NASDAQ: HCM) announced that it has entered into a definitive agreement for the sale of $100 million of shares at $25 per ADS through a private placement to private equity firm General Atlantic.This fundraise could increase to $200 million through a warrant granted with a term of 18 months for a further $100 million in Chi-Med shares exercisable at a price per share equivalent to $30 per ADS, the company said. Erytech Pharma SA (NASDAQ: ERYP) announced the signing of an agreement with the Luxembourg-based European High Growth Opportunities Securitization Fund for issuing convertible notes valued up to a maximum of 60 million euros ($67.2 million) in the event of conversion of all the notes, subject to the regulatory limit of 20% dilution.View more earnings on IBBErytech said the financing line aims at improving its financial strength and extending its cash horizon for the next key development milestones.Xeris Pharmaceuticals Inc (NASDAQ: XERS) said it has commenced concurrent underwritten public offerings of $20 million in shares of its common stock and $60 million in aggregate principal amount of convertible senior notes due 2025. The company expects the net proceeds to finance the commercialization of Gvoke and repay a $20 million loan, among other things.The stock was down 19.96% at $4.25 premarket. Evelo Biosciences Inc (NASDAQ: EVLO) priced its underwritten public offering of 12 million shares of its common stock at $3.75 per share for gross proceeds of $45 million. All of the shares in the offering are to be sold by the company. The offering is expected to close on or about June 29.The stock was down 8.98% at $3.65 premarket. Nantkwest Inc (NASDAQ: NK) priced its underwritten public offering of 7.41 million shares, with 3.7 million shares to be priced at $9.50 per share and the remaining 3.7 million shares at $12.12 per share to its CEO and principal stockholder Dr. Patrick Soon-Shiong. The aggregate gross proceeds from the offering are expected to be approximately $80.1 million.In after-hours trading, the stock shed 9.39% to $11.Translate Bio said it has commenced an underwritten public offering of $125 million of its common stock. In addition, Shire, a subsidiary of Takeda Pharmaceutical Co Ltd (NYSE: TAK), is offering 6.825 million of its common stock in the offering. The company clarified that it will not receive any proceeds from the shares sold by Shire.Translate Bio shares were down 6.64% at $24.89 premarket Thursday.Magenta Therapeutics Inc (NASDAQ: MGTA) priced its underwritten public offering of 7.5 million shares of its common stock at $8 per share for gross proceeds of $60 million. All the shares earmarked for the offering are sold by the company.On The Radar PDUFA Dates The FDA is set to rule on Zogenix, Inc.'s (NASDAQ: ZGNX) NDA for Fintepla as a potential treatment candidate for seizures associated with Dravet syndrome.Earnings * Aethlon Medical, Inc. (NASDAQ: AEMD) (after the close)Related Link: Evoke Gets FDA Nod For Gimoti, A Nasally-Administered Gastroparesis Drug See more from Benzinga * The Daily Biotech Pulse: MediciNova On Track For European Patent Win, Partial Clinical Hold Lifted For Innate Pharma, Tela Bio Details Coronavirus Impact * The Daily Biotech Pulse: Sanofi Expedites COVID-19 Vaccine Timeline, Apyx Cleared For Market Expansion, Miragen's Positive Readout(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 06/25/2020
|
The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene Therapy
- The following is a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 24)
ACADIA...
- 06/25/2020
|
BrainStorm to study stem cell treatment in Alzheimer's patients
- BrainStorm Cell Therapeutics Inc said on Wednesday it will begin a clinical trial of its experimental stem cell treatment in patients with Alzheimer's disease. The U.S.-Israeli company is already conducting advanced trials of its treatment called NurOwn in patients with the neurodegenerative disease amyotrophic lateral sclerosis (ALS). It also received U.S. regulatory clearance for a Phase 2 multicenter trial in progressive multiple sclerosis.
- 06/24/2020
|
Reuters Health News Summary
- There were 2,531 new coronavirus infections reported in the past 24 hours, raising the total number of cases to 212,501, along with 9,996 deaths in all, the ministry said on Wednesday.
- 06/24/2020
|
BrainStorm to study stem cell treatment in Alzheimer's patients
- BrainStorm Cell Therapeutics Inc said on Wednesday it will begin a clinical trial of its experimental stem cell treatment in patients with Alzheimer's disease.
- 06/24/2020
|
BrainStorm Expands Clinical Pipeline to Evaluate NurOwn® for the Treatment of Alzheimer's Disease
- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced a new clinical program focused on the development of NurOwn® as a treatment for Alzheimer's disease. As part of the newly announced program, the Company is planning a multi-national Phase 2 clinical trial to evaluate the safety and efficacy of NurOwn treatment in patients with prodromal to mild Alzheimer's disease.
- 06/24/2020
|
Lineage Cell Therapeutics to Present OpRegen® Data at International Society for Stem Cell Research (ISSCR) 2020 Virtual Annual Meeting
- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medic
- 06/24/2020
|
Maxim Group Thinks BioNano Genomics' Stock is Going to Recover - Markets
- In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on BioNano Genomics (BNGO – Research
- 06/23/2020
|
BrainStorm Cell Therapeutics to Join the Russell 2000® Index and Russell 3000® Index
- BrainStorm Cell Therapeutics Inc. (NasdaqCM: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that its shares will join the Russell 2000® Index and the broad-market Russell 3000® Index at the conclusion of the 2020 Russell indexes annual reconstitution, effective after the US stock market opens on June 29, 2020.
- 06/23/2020
|
Maxim Group Assigns a Buy Rating on Heat Biologics (HTBX) - Markets
- Maxim Group analyst Jason McCarthy assigned a Buy rating to Heat Biologics (HTBX – Research Report) today and set a
- 06/19/2020
|
Annovis Bio (ANVS) Initiated with a Buy at Maxim Group - Markets
- Maxim Group analyst Jason McCarthy initiated coverage with a Buy rating on Annovis Bio (ANVS – Research Report) today and
- 06/19/2020
|
Analysts Offer Insights on Healthcare Companies: Armata Pharmaceuticals (NYSE MKT: ARMP), BioMarin Pharmaceutical (NASDAQ: BMRN) and Trillium Therapeutics (NASDAQ: TRIL) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Armata Pharmaceuticals
- 06/18/2020
|
The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 17)
Adverum Biotechnologies Inc...
- 06/18/2020
|
Researchers make 'self-cleaning' face mask
- Israeli researchers say they have invented a reusable face mask that can kill the coronavirus with heat by drawing power from a mobile phone charger.
- 06/17/2020
|
Researchers make 'self-cleaning' face mask powered by everyday item
- Researchers at Technion University in Israel have invented a reusable face mask that can kill the coronavirus with heat.
- 06/17/2020
|
Self-Cleaning Masks Can Kill COVID-19 With Phone Charger's Heat: Researchers
- Israeli researchers say they have invented a reusable face mask that can kill the coronavirus with heat by drawing power from a mobile phone charger.
- 06/17/2020
|
Self-cleaning mask can kill viruses with heat from phone charger, researchers say
- Israeli researchers say they have invented a reusable face mask that can kill the coronavirus with heat by drawing power from a mobile phone charger.
- 06/17/2020
|
Self-cleaning mask can kill viruses with heat from phone charger, researchers say
- Israeli researchers say they have invented a reusable face mask that can kill the coronavirus with heat by drawing power from a mobile phone charger.
- 06/17/2020
|
The Daily Biotech Pulse: Patent Win For Amarin, FDA Nod For Novartis & Merck, Chembio's Coronavirus EUA Revoked
- Here's a roundup of top developments in the biotech space over the last 24 hour.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 16)
ADC Therapeutics SA (NYSE:...
- 06/17/2020
|
Navidea (NAVB) Gets a Buy Rating from Maxim Group - Markets
- Maxim Group analyst Jason McCarthy assigned a Buy rating to Navidea (NAVB – Research Report) today and set a price
- 06/16/2020
|
The Daily Biotech Pulse: GlaxoSmithKline, IDEAYA Strike Oncology Partnership, Decision Day For Merck, Adverum's New CEO
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 16)
Applied Molecular Transport...
- 06/16/2020
|
BrainStorm Granted SME Status by the European Medicines Agency
- NEW YORK, June 15, 2020 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced.
- 06/15/2020
|
Pat Quinn launches handlebar mustache challenge for ALS research
- The Mighty Pat Quinn is rallying people to raise money for ALS research through his #Handlebars4Hope challenge throughout the month of June.
- 06/12/2020
|
BrainStorm to Present at the Raymond James Human Health Innovations Conference
- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Chaim Lebovits, CEO and Ralph Kern, MD, MHSc, President and Chief Medical Officer, will present a corporate overview on Thursday, June 18 at 9:00 am EST, during the Raymond James Human Health Innovations Conference, a virtual event connecting institutional investors with company management teams that will be held June 15-18, 2020.
- 06/11/2020
|
BCLI: ALS Association and I AM ALS Awards $500,000 Grant; Potential Inclusion in Russell 3000 Index…
- By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update $500,000 Grant from ALS Association and I AM ALS On June 9, 2020, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) announced a combined grant of $500,000 from the ALS Association and I AM ALS to support an ALS biomarker study utilizing samples and data from the ongoing Phase 3 clinical trial of NurOwn® in ALS
- 06/10/2020
|
The ALS Association, I AM ALS Award BrainStorm Cell Therapeutics $500,000 for ALS Biomarker Study
|
The ALS Association, I AM ALS Award BrainStorm Cell Therapeutics $500,000 for ALS Biomarker Study
- The ALS Association and I AM ALS announced today that the organizations have awarded a combined grant of $500,000 to BrainStorm Cell Therapeutics (NASDAQ: BCLI), a biotechnology company, to support an amyotrophic lateral sclerosis (ALS) biomarker research study. The grant will be used to draw insights from data and samples collected from patients enrolled in BrainStorm's ongoing phase 3 clinical trial of its NurOwn® treatment, to further understanding of critical biomarkers associated with treatment response for people with ALS.
- 06/09/2020
|
Hedge Funds Warming Up To Brainstorm Cell Therapeutics Inc. (BCLI)
- We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. In this article, we look at what those funds think […]
- 06/04/2020
|
BrainStorm to Participate in BIO Digital 2020
- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Dr. Ralph Kern, M.D, President and Chief Medical Officer will present a corporate overview during the BIO International Convention, which has transitioned to a new and virtual event and has been renamed BIO Digital. During BIO Digital, Dr. Kern will update conference participants on the Company's investigational therapeutic NurOwn® that is currently in a phase 3 study for the treatment of ALS and a phase 2 study for the treatment of progressive multiple sclerosis, and present an overview of the Company's pipeline. Additionally, Mr. Chaim Lebovits, CEO of BrainStorm, and other members of the BrainStorm management team will participate in one-on-one digital partnering meetings, which registered conference participants can request by utilizing the BIO Partnering link provided by conference organizers.
- 06/03/2020
|
BrainStorm Announces That Pivotal Phase 3 Trial Remains On Track For Topline Data In Q4-2020
|
BrainStorm Announces that Pivotal Phase 3 Trial Remains on Track for Topline Data in Q4-2020
- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today an update on the Company's Phase 3 pivotal trial investigating NurOwn® in ALS. The Company continues to expect that top-line data from the trial will be announced by Q4-2020, despite the ongoing COVID-19 pandemic that has delayed hundreds of other clinical trials around the world.
- 06/02/2020
|
Cancer-stricken boy's given a year to live, so best friend plans a 127-item bucket list
- Dillon Hill dropped out of college to help his terminally ill friend complete his bucket list. Now, he's continuing a mission of giving back.
- 06/01/2020
|
65% Of Small Israeli Start-ups Could Succumb To COVID-19: Survey
- 65% of small Israeli start-ups could succumb to COVID-19: survey
- 05/31/2020
|
Yogi Adityanath ropes in industry to provide 7.5 lakh jobs; UP moves to solve migrant labour woes
- With the unemployment crisis for migrant workers looming large, Chief Minister Yogi Adityanath has moved to address the labour woes by roping in industries to provide for as many as 7.5 lakh jobs in the state of Uttar Pradesh.
- 05/28/2020
|
BrainStorm Appoints Pharmaceutical Veteran Stacy R. Lindborg, Ph.D. as Executive Vice President, Head of Global Clinical Research
- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that Stacy R. Lindborg, Ph.D. has been appointed Executive Vice President Head of Global Clinical Research effective June 1, 2020. Dr. Lindborg is an experienced healthcare professional and globally recognized medical statistician with over 24 years of multinational experience in R&D;, regulatory, strategy development, analytics and big data.
- 05/27/2020
|
Virus slices into ALS dividends, but silver lining on horizon
- The Brisbane-based testing giant also says some coal customers have backed its transparency in an analysis scandal.
- 05/27/2020
|
Children’s Healing Art Project (CHAP) Launches #CHAPPYFEET Challenge
- Make Art With Your Feet. The CHAPpy Feet Challenge FUNdraiser Brings Art To Kids and Families In Medical Crisis. Help The Non-Profit Bring Art to Kids
- 05/20/2020
|
Does The Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Share Price Tend To Follow The Market?
- If you own shares in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) then it's worth thinking about how it contributes...
- 05/18/2020
|
QurAlis raises $42M in Series A round to develop therapies for ALS
- Startup companies that have raised closed funding rounds in the past week also include C2N Diagnostics, Carbon Health, Stellar Health and Modulus Discovery.
- 05/17/2020
|
How to buy ALS shares | 18 May price A$6.28 | Finder
- Ever wondered how to buy shares in ALS? We explain how and compare the best share trading platforms. Latest ALS share price is A$6.28.
- 05/13/2020
|
Non-Small Cell Lung Cancer (NSCLC) Market Insights and Epidemiology 2017-2030 - ResearchAndMarkets.com
|
BrainStorm Cell Therapeutics Inc. (BCLI) CEO Chaim Lebovits on Q1 2020 Results - Earnings Call Transcript
- BrainStorm Cell Therapeutics Inc. BCLI) Q1 2020 Earnings Conference Call May 7, 2020 8:00 AM ET Company Participants Sean Leous - ICR Westwicke Chaim Lebovits -
- 05/10/2020
|
BCLI: The Countdown to Phase 3 ALS Data Begins…
- By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Phase 3 ALS Topline Data in 4Q20 BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) is currently conducting a Phase 3 clinical trial of NurOwn® in patients with amyotrophic lateral sclerosis (ALS) (NCT03280056). A total of 200 patients were randomized 1:1 to receive NurOwn® or placebo in the randomized, double blind,
- 05/08/2020
|
84 Biggest Movers From Yesterday
|
Brainstorm Cell Q1 EPS $(0.320) Misses $(0.220) Estimate
|
BrainStorm Announces Financial Results for the First Quarter of 2020 and Provides a Corporate Update
- Conference Call and Webcast Today at 8:30 a.m. Eastern Time ALS Phase 3 Clinical Trial Remains on Track for Q4’20 Top-line Data Readout NEW YORK, May 07, 2020 -- BrainStorm.
- 05/07/2020
|
BrainStorm Leases a New Cleanroom Facility at The Tel Aviv Sourasky Medical Center to Manufacture NurOwn® for The European Union
|
BrainStorm Leases a New Cleanroom Facility at The Tel Aviv Sourasky Medical Center to Manufacture NurOwn® for The European Union
- NEW YORK, N.Y., and TEL AVIV, Israel, May 07, 2020 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative.
- 05/07/2020
|
The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks hitting 52-week highs May 6.)
Adverum Biotechnologies Inc...
- 05/07/2020
|
BrainStorm Presents New Data Highlighting NurOwn® Immunomodulation in Neurology
- NEW YORK, May 04, 2020 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced.
- 05/04/2020
|
BrainStorm Presents New Data Highlighting NurOwn® Immunomodulation in Neurology
|
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
- Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
- 05/03/2020
|
BrainStorm-Cell Therapeutics to Announce First Quarter Financial Results and Provide a Corporate Update
- NEW YORK, April 29, 2020 -- BrainStorm-Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating.
- 04/29/2020
|
Acceleron Pharma (NASDAQ:XLRN) vs. Brainstorm Cell Therapeutics (NASDAQ:BCLI) Financial Comparison
- Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Acceleron Pharma (NASDAQ:XLRN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings. Analyst Recommendations This is a breakdown of current recommendations and price targets for Brainstorm Cell […]
- 04/13/2020
|
Analysts Anticipate Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) to Post -$0.22 EPS
- Brokerages expect that Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) will post ($0.22) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Brainstorm Cell Therapeutics’ earnings. Brainstorm Cell Therapeutics reported earnings of ($0.24) per share during the same quarter last year, which suggests a positive year-over-year growth rate of […]
- 04/11/2020
|
Abner Herrman & Brock Llc Buys Synopsys Inc, Air Products & Chemicals Inc, Pfizer Inc, ...
|
BCLI: $1.5M Grant from Israel Innovation Authority…
- By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Coronavirus Epidemic Not Affecting Business Operations In March 2020, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) held a conference call to provide an update regarding the company’s current and ongoing business operations
- 04/08/2020
|
Sankesh Abbhi Reports 9.04% Stake In Brainstorm Cell Therapeutics Inc As Of March 30
|
Bio Roundup: Biotech Billions, COVID-19 R&D, Zolgensma’s Path & More
- The coronavirus pandemic has shaken the global economy, but three life sciences venture capital firms this week announced new funds totaling nearly $3
- 04/03/2020
|
BrainStorm Wins $1.5M Non-Dilutive Grant By Israel Innovation Authority
|
BrainStorm Awarded $1.5 Million Non-Dilutive Grant for 2020 by the Israel Innovation Authority
- NEW YORK and PETACH TIKVAH, Israel, April 03, 2020 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for.
- 04/03/2020
|
BrainStorm Awarded $–.5 Million Non-Dilutive Grant for —…—… by the Israel Innovation ...
|
Brainstorm Cell Therapeutics Names Setboun Chief Operating Officer
- David Setboun has been appointed executive vice president and chief operating officer of Brainstorm Cell Therapeutics (NASDAQ: ]). He is joining New
- 04/02/2020
|
David Setboun Joins BrainStorm as Executive Vice President and Chief Operating Officer
- International Pharmaceutical Veteran to Lead Global Business and Commercial Development Ralph Kern, MD, MHSc, Promoted to President NEW YORK, April 01, 2020 -- BrainStorm.
- 04/01/2020
|
BrainStorm Appoints Prof. Jacob Frenkel Chairman of the Board of Directors
|
BrainStorm Appoints Renowned Distinguished Economist, Prof. Jacob Frenkel, Chairman of the Board of Directors
- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cell technologies for neurodegenerative diseases, today announced the appointment of Jacob Frenkel, Ph.D., as Chairman of the Board of Directors. Prof. Frenkel, a world-renowned economist and former Governor of the Bank of Israel
- 03/31/2020
|
Analyzing Denali Therapeutics (NASDAQ:DNLI) and Brainstorm Cell Therapeutics (NASDAQ:BCLI)
- Denali Therapeutics (NASDAQ:DNLI) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, institutional ownership, earnings and risk. Insider & Institutional Ownership 67.1% of Denali Therapeutics shares are owned by institutional investors. […]
- 03/26/2020
|
Global Autologous Cell Therapy Market 2020-2024 | Evolving Opportunities with Bayer AG and Brainstorm Cell Therapeutics Inc. | Technavio
- The autologous cell therapy market size has the potential to grow by USD 1.97 billion during 2020-2024.
- 03/24/2020
|
Brainstorm Therapeutics Shares Pare All Recent Gains Since Trader Circulation Of Co. Tweet; Shares Still Up 8% for Session
|
The Global Autologous Cell Therapy Market is expected to grow by USD 1.97 bn during 2020-2024, progressing at a CAGR of 22% during the forecast period
- Global Autologous Cell Therapy Market 2020-2024 The analyst has been monitoring the global autologous cell therapy market 2020-2024 and it is poised to grow by USD 1.97 bn during 2020-2024, progressing at a CAGR of 22% during the forecast period. Our reports on global autologous cell therapy market 2020
- 03/20/2020
|
130 Biggest Movers From Yesterday
- Gainers
Blue Apron Holdings, Inc. (NYSE: APRN) shares gained 71.5% to close at $6.55 after surging over 67% on Monday.
BioNTech SE (NASDAQ: BNTX) gained 66.5% to close at $66.60...
- 03/18/2020
|
94 Stocks Moving In Tuesday's Mid-Day Session
- Gainers
Waitr Holdings Inc. (NASDAQ: WTRH) jumped 64.1% to $0.9042 after surging 75% on Monday.
BioNTech SE (NASDAQ: BNTX) gained 60.6% to $64.24. Pfizer and BioNTech confirmed...
- 03/17/2020
|
BrainStorm to Hold a Conference Call to Update Investors on Corporate Steps Taken to Address COVID-19
- Funding Secured and Senior Management Team Activated by CEO to Ensure Advancement of all Operational Activities and Completion of Corporate Clinical Milestones Call.
- 03/16/2020
|
BrainStorm to Hold a Conference Call to Update Investors on Corporate Steps Taken to Address COVID-19
|
100 Biggest Movers From Friday
|
BrainStorm Cell Therapeutics Raises $10.0 Million in Common Stock Sale at $8.00 Per Share
- BrainStorm Cell Therapeutics Inc., (NASDAQ: BCLI), a leading developer of cell technologies for neurodegenerative diseases, today announced that it has entered into a definitive agreement with Abbhi Investments, LLC, a healthcare-focused family office based in Miami, Florida, in connection with a privately negotiated sale of common stock and a warrant to purchase common stock (collectively, the “securities”). Upon the closing of this registered direct offering, BrainStorm will receive gross proceeds of $10.0 million, resulting from the issuance and sale of 1,250,000 shares of common stock at a price per share of $8.00, a 4.9% premium to our closing share price of $7.62 on March 5, 2020, and a 35.6% premium to the 30 day volume-weighted average price of $5.90.
- 03/06/2020
|
101 Biggest Movers From Yesterday
- Gainers
Cohen & Company Inc. (NYSE: COHN) shares climbed 27.8% to close at $5.11 on Thursday. The Israeli company posted a Q4 profit of $0.56 per share, versus a year-ago...
- 03/06/2020
|
BrainStorm Cell Therapeutics Prices 1.25M Common Stock Offering At $8/Share
|
Thursday’s Midday Stock Update: Calamp Crop (CAMP), Inovio Pharmaceuticals (INO), Novavax (NVAX), Brainstorm Cell Therapeutics (BCLI), Kroger Company (KR)
- So far Thursday, March 5, NASDAQ is up 0.22% and the S&P is down -0.82%. Here are this morning’s most
- 03/05/2020
|
Coal miner's 'fake analysis' probe never queried lab
- TerraCom has resoundingly rejected claims that its coal quality had been faked.
- 03/01/2020
|
Fifth and Final Site Announced for BrainStorm’s Progressive Multiple Sclerosis Phase 2 Clinical Trial
- NEW YORK and BOSTON, Feb. 27, 2020 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating.
- 02/27/2020
|
95 Biggest Movers From Yesterday
|
Wednesday’s Midday Stock Update: Coca-Cola Bottling Co Consolidated (COKE), Peabody Energy Comm (BTU), Novavax (NVAX), Brainstorm Cell Therapeutics (BCLI), Clovis Oncology (CLVS)
- So far Wednesday, February 26, NASDAQ is up 0.4% and the S&P is down -0.43%. Let’s take a look at
- 02/26/2020
|
The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 25) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) (Cowen ...
- 02/26/2020
|
80 Biggest Movers From Yesterday
- Gainers
Nemaura Medical Inc. (NASDAQ: NMRD) shares jumped 77.4% to close at $5.80 on Tuesday.
Cocrystal Pharma Inc (NASDAQ: COCP) shares surged 64.7% to close at $2.19 on...
- 02/26/2020
|
Tuesday’s Midday Stock Update: Clovis Oncology (CLVS), Brainstorm Cell Therapeutics (BCLI), Cytosorbents (CTSO), Heron Therapeutics (HRTX), Agios Pharma (AGIO)
- So far Tuesday, February 25, NASDAQ is down -5.98% and the S&P is down -5.61%. Here are this morning’s most
- 02/25/2020
|
55 Stocks Moving In Tuesday's Mid-Day Session
- Gainers
Cocrystal Pharma Inc (NASDAQ: COCP) climbed 79% to $2.38 S
Mallinckrodt plc (NYSE: MNK) climbed 33.6% to $5.57 after the company announced a global opioid settlement...
- 02/25/2020
|
The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 24) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI ) Co-Diagnostics Inc (NASDAQ: CODX )(received CE mark for its coronavirus test) COLLPLANT BIOTE/S ADR (NASDAQ: CLGN ) Gilead Sciences, Inc. (NASDAQ: GILD )(reacted to a statement from WHO that its experimental drug remdesivir could be the one drug that may have efficacy) NGM Biopharmaceuticals Inc (NASDAQ: NGM )( reacted to positive readout for its NASH drug) PAVmed Inc (NASDAQ: PAVM ) TELA Bio Inc (NASDAQ: TELA ) Zynex Inc. (NASDAQ: ZYXI ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on Feb. 24) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Acorda Therapeutics Inc (NASDAQ: ACOR ) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) AngioDynamics, Inc. (NASDAQ: ANGO ) BioSig Technologies Inc (NASDAQ: BSGM ) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) Endologix, Inc.
- 02/25/2020
|
6 Stock Charts To Watch: EGO, GILD, LAKE, SURF, TVIX, ZYXI6
- Stocks Analysis by Harry Boxer covering: Gilead Sciences Inc, Lakeland Industries Inc, Eldorado Gold Corp, ProShares Ultra VIX Short-Term Futures ETF. Read Harry Boxer's latest article on Investing.com
- 02/25/2020
|
Monday’s Midday Stock Update: Brainstorm Cell Therapeutics (BCLI), La Jolla Pharma (LJPC), Clovis Oncology (CLVS), Karyopharm Therapeutics (KPTI), Navios Maritime Partners (NMM)
- So far Monday, February 24, NASDAQ is up 0.33% and the S&P is down -0.32%. Here are this morning’s most
- 02/24/2020
|
94 Biggest Movers From Friday
- Gainers
Trans World Entertainment Corporation (NASDAQ: TWMC) shares jumped 50.9% to close at $5.28 on Friday after the company disclosed that its subsidiary etailz entered into a...
- 02/24/2020
|
55 Stocks Moving In Monday's Mid-Day Session
|
Friday’s Highlights at Noon: Mallinckrodt (MNK), Peabody Energy Comm (BTU), Rite Aid (RAD), Glu Mobile (GLUU), Brainstorm Cell Therapeutics (BCLI)
- So far Friday, February 21, NASDAQ is down -1.87% and the S&P is down -1.22%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Mallinckrodt (
MNK
–
Research Report
), Peabody Energy Comm (
BTU
–
Research Repor
- 02/21/2020
|
BCLI: Phase 3 ALS Results in 4Q20…
|
80 Biggest Movers From Yesterday
|
Tuesday’s Midday Stock Update: Cytokinetics (CYTK), Brainstorm Cell Therapeutics (BCLI), SunPower (SPWR), Sprint (S), Ballard Power Systems (BLDP)
- So far Tuesday, February 18, NASDAQ is down -1.34% and the S&P is down -0.7%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Cytokinetics (
CYTK
–
Research Report
), Brainstorm Cell Therapeutics (
BCLI
–
Res
- 02/18/2020
|
35 Healthcare Stocks Moving In Tuesday's Pre-Market Session
- Gainers
Stealth BioTherapeutics, Inc. (NASDAQ: MITO) stock increased by 38.4% to $3.10 during Tuesday's pre-market session. According to the most recent rating by H...
- 02/18/2020
|
BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2019
- NEW YORK, Feb. 18, 2020 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announces.
- 02/18/2020
|
BrainStorm's Chief Operating Officer to Present at Noble Capital Markets' Sixteenth Annual ...
|
Sunday’s Midday Movers: Brainstorm Cell Therapeutics (BCLI), Xoma (XOMA), SunPower (SPWR), Karyopharm Therapeutics (KPTI), Blueprint Medicines (BPMC)
- So far Sunday, February 16, NASDAQ is down -2.8% and the S&P is up 0.09%. Let’s take a look at
- 02/16/2020
|
The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering
- The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 13.) Anavex Life Sciences Corp (NASDAQ: AVXL ) AtriCure Inc. (NASDAQ: ATRC ) Beam Therapeutics Inc (NASDAQ: BEAM ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI ) ChemoCentryx Inc (NASDAQ: CCXI ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCM ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Fortress Biotech (NASDAQ: FBIO ) Insulet Corporation (NASDAQ: PODD ) Krystal Biotech Inc (NASDAQ: KRYS ) Masimo Corporation (NASDAQ: MASI ) NeoGenomics, Inc. (NASDAQ: NEO ) Nevro Corp (NYSE: NVRO ) Recro Pharma Inc (NASDAQ: REPH ) ResMed Inc. (NYSE: RMD ) Revolution Medicines Inc (NASDAQ: RVMD ) (went public Thursday) Syneos Health Inc (NASDAQ: SYNH ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) Taro Pharmaceutical Industries Ltd. (NYSE: TARO ) West Pharmaceutical Services Inc.
- 02/14/2020
|
77 Biggest Movers From Yesterday
- Gainers
Revolution Medicines, Inc. (NASDAQ: RVMD) shares surged 70% to close at $28.90 on Thursday. Revolution Medicines priced 14 million share IPO at $17 per share.
BioXcel...
- 02/14/2020
|
The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 12) AbbVie Inc (NYSE: ABBV ) Agile Therapeutics Inc (NASDAQ: AGRX ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Allergan plc (NYSE: AGN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Anavex Life Sciences Corp (NASDAQ: AVXL ) Aptose Biosciences Inc (NASDAQ: APTO ) AtriCure Inc. (NASDAQ: ATRC ) AVITA MED LTD/S ADR (NASDAQ: RCEL ) Avrobio Inc (NASDAQ: AVRO ) Beam Therapeutics Inc (NASDAQ: BEAM ) Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI ) ChemoCentryx Inc (NASDAQ: CCXI ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCM ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Fate Therapeutics Inc (NASDAQ: FATE ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Masimo Corporation (NASDAQ: MASI ) Medpace Holdings Inc (NASDAQ: MEDP ) NeoGenomics, Inc. (NASDAQ: NEO ) Novartis AG (NYSE: NVS ) Ocular Therapeutix Inc (NASDAQ: OCUL ) PAVmed Inc (NASDAQ: PAVM ) Penumbra Inc (NYSE: PEN ) Prevail Therapeutics Inc (NASDAQ: PRVL )(reacted to the FDA according Orphan Drug Designation to its experimental gene therapy PR001 for treating Gaucher disease) PTC Therapeutics, Inc (NASDAQ: PTCT ) Repligen Corporation (NASDAQ: RGEN ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) West Pharmaceutical Services Inc.
- 02/13/2020
|
Stocks That Hit 52-Week Highs On Thursday
|
94 Biggest Movers From Yesterday
- Gainers
Rexahn Pharmaceuticals, Inc. (NASDAQ: REXN) shares gained 78.5% to close at $3.66 after the company announced a license agreement with Zhejiang HaiChang Biotechnology....
- 02/12/2020
|
Stocks That Hit 52-Week Highs On Wednesday
|
BrainStorm Cell Therapeutics and FDA Agree to Potential NurOwn Regulatory Pathway for Approval in ALS
|
BrainStorm Cell Therapeutics to Announce Fourth Quarter and Full Year —…–9 Financial ...
|
BrainStorm CEO to Provide Company Update at the BIO CEO & Investor Conference
|
BrainStorm Receives Notice of Intention to Grant Additional EU Patent for NurOwn
|
Investors test share limits at lab outfit ALS
- ALS in testing giant keep rising even as analysts say hold. What's the upside, and downside, risks ahead?
- 01/12/2020
|
Translate Bio (NASDAQ:TBIO) versus Brainstorm Cell Therapeutics (NASDAQ:BCLI) Head to Head Comparison
- Translate Bio (NASDAQ:TBIO) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation. Valuation & Earnings This table compares Translate Bio and Brainstorm Cell Therapeutics’ gross revenue, […]
- 01/11/2020
|
BrainStorm Issues 2019 Letter to Shareholders
|
BrainStorm Cell Therapeutics Reports Mount Sinai Medical Center Has Contracted With Co. As Clinical Study Stie For Co.'s Phase 2 Label For NurOwn
|
Brainstorm Cell Therapeutics 13D From Joseph Daly Shows 4.58% Stake, Karina Daly Shows 0.37% Stake, EssigPR Shows 0.61% Stake
|
TGT, MYOV among premarket gainers
|
BrainStorm Cell Therapeutics Reports Receives $495.33K Grant From National Multiple Sclerosis Society To Advance Co.'s Phase 2 Open-Label, Multicenter Clinical Trial Of Repeated Intrathecal Administration Of NurOwn
|
Brainstorm nabs NurOwn patent in Japan
|
BrainStorm Cell Therapeutics Announces COO Ralph Kern MD MHSc to Present at the 7th International Stem Cell Meeting
|
Interview With Chaim Lebovits, CEO Of Brainstorm Cell Therapeutics
|
BrainStorm Cell Therapeutics' Data Safety Monitoring Board Recommends ALS Phase 3 Clinical Trial Continue
|
BrainStorm Cell Therapeutics to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference on October 29
|
BrainStorm Cell Therapeutics' President and CEO to be Featured as Keynote Speaker at Cell ...
|
BrainStorm Cell Therapeutics Presentations at Neuromuscular Drug Development Summit
|
BrainStorm Says NurOwn Phase 3 ALS Clinical Trial Now Fully Enrolled
|
BrainStorm Announces Notice of US Patent Allowance for NurOwn® Cellular Therapeutic Technology ...
|
